Neuraxis Inc

Neuraxis Inc has a negative equity position of -$3.18 billion and a debt-to-equity ratio of -0.44, indicating a capital structure heavily reliant on debt financing. The company's liquidity position is weak, with a current ratio of 0.11 and only $81,750 in cash and equivalents, which is insufficient to cover its $4.13 billion in total liabilities. The negative free cash flow of -$2.12 billion and operating cash flow of -$1.33 billion further highlight the company's cash flow challenges. Profitability metrics are deeply negative, with a net loss of -$2.12 billion and an operating loss of -$1.83 billion. Return on equity is a marginal 0.6659, while return on assets is -2.2423, both significantly below industry norms for medical equipment and supplies firms. Gross profit of $571.56 million is insufficient to offset operating expenses, contributing to the company's unprofitable position. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to sector-specific risks and limits growth opportunities. No material revenue concentration by geography is reported, but the absence of segmental or geographic breakdowns in the financial data suggests a lack of transparency in operational exposure. Growth prospects are constrained by the company's current financial position. The company is not reporting revenue growth, and no forward-looking guidance is provided in the available data. Analysts have assigned a mean price target of $11.00, suggesting a potential upside of 31.6% from the current market price of $8.35. However, the absence of positive earnings and the company's negative equity position limit the credibility of these estimates. The company faces significant liquidity and solvency risks, with a negative net cash position and a high debt load. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative equity position and high leverage suggest a high probability of financial distress. No dilution sources are disclosed, but the company's capital structure and negative equity position imply a potential need for equity financing in the near term. Recent events include the publication of the latest financial data, which reveals the company's deteriorating financial position. No recent filings or transcripts are available to provide additional context on the company's strategic direction or operational performance.